These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34117987)

  • 41. Strengthening national decision-making on immunization by building capacity for economic evaluation: Implementing ProVac in Europe.
    Blau J; Hoestlandt C; D Clark A; Baxter L; Felix Garcia AG; Mounaud B; Mosina L
    Vaccine; 2015 May; 33 Suppl 1():A34-9. PubMed ID: 25919171
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of health technology assessment and managed entry schemes on reimbursement decisions of centrally authorised medicinal products in Belgium.
    Van Wilder P; Pirson M; Dupont A
    Eur J Clin Pharmacol; 2019 Jul; 75(7):895-900. PubMed ID: 30877328
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exploring payment schemes used to promote integrated chronic care in Europe.
    Tsiachristas A; Dikkers C; Boland MR; Rutten-van Mölken MP
    Health Policy; 2013 Dec; 113(3):296-304. PubMed ID: 23937868
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Managed Entry Agreements: Policy Analysis From the European Perspective.
    Dabbous M; Chachoua L; Caban A; Toumi M
    Value Health; 2020 Apr; 23(4):425-433. PubMed ID: 32327159
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.
    Kleijnen S; Lipska I; Leonardo Alves T; Meijboom K; Elsada A; Vervölgyi V; d'Andon A; Timoney A; Leufkens HG; De Boer A; Goettsch WG
    Ann Oncol; 2016 Sep; 27(9):1768-75. PubMed ID: 27329251
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.
    Facey KM; Espin J; Kent E; Link A; Nicod E; O'Leary A; Xoxi E; van de Vijver I; Zaremba A; Benisheva T; Vagoras A; Upadhyaya S
    Pharmacoeconomics; 2021 Sep; 39(9):1021-1044. PubMed ID: 34231135
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
    Akehurst RL; Abadie E; Renaudin N; Sarkozy F
    Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pre-assessment to assess the match between cost-effectiveness results and decision makers' information needs: an illustration using two cases in rehabilitation medicine in The Netherlands.
    IJzerman MJ; Reuzel RP; Severens HL
    Int J Technol Assess Health Care; 2003; 19(1):17-27. PubMed ID: 12701936
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An Ethical Analysis of Coverage With Evidence Development.
    Carter D; Merlin T; Hunter D
    Value Health; 2019 Aug; 22(8):878-883. PubMed ID: 31426928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT FOR THE ADOPTION OF INNOVATIVE MEDICAL DEVICES WITHIN FRENCH HOSPITALS: OPPORTUNITIES AND CHALLENGES FOR INDUSTRY.
    Dutot C; Mercier G; Borget I; de Sauvebeuf C; Martelli N
    Int J Technol Assess Health Care; 2017 Jan; 33(2):297-302. PubMed ID: 28578711
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Coverage with evidence development: an examination of conceptual and policy issues.
    Hutton J; Trueman P; Henshall C
    Int J Technol Assess Health Care; 2007; 23(4):425-32. PubMed ID: 17937829
    [TBL] [Abstract][Full Text] [Related]  

  • 52. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
    Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
    Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of health technology assessment in coverage decisions on newborn screening.
    Fischer KE; Grosse SD; Rogowski WH
    Int J Technol Assess Health Care; 2011 Oct; 27(4):313-21. PubMed ID: 22004771
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Budgeting for a billion: applying health technology assessment (HTA) for universal health coverage in India.
    Dabak SV; Pilasant S; Mehndiratta A; Downey LE; Cluzeau F; Chalkidou K; Luz ACG; Youngkong S; Teerawattananon Y
    Health Res Policy Syst; 2018 Nov; 16(1):115. PubMed ID: 30486827
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Similarities and differences between stakeholders' opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey.
    Vokó Z; Cheung KL; Józwiak-Hagymásy J; Wolfenstetter S; Jones T; Muñoz C; Evers SM; Hiligsmann M; de Vries H; Pokhrel S;
    Health Res Policy Syst; 2016 May; 14(1):38. PubMed ID: 27230485
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Health Care Coverage Decision Making in Low- and Middle-Income Countries: Experiences from 25 Coverage Schemes.
    Gutierrez H; Shewade A; Dai M; Mendoza-Arana P; Gómez-Dantés O; Jain N; Khonelidze I; Nabyonga-Orem J; Saleh K; Teerawattananon Y; Nishtar S; Hornberger J
    Popul Health Manag; 2015 Aug; 18(4):265-71. PubMed ID: 25393442
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combining multi-criteria decision analysis and mini-health technology assessment: A funding decision-support tool for medical devices in a university hospital setting.
    Martelli N; Hansen P; van den Brink H; Boudard A; Cordonnier AL; Devaux C; Pineau J; Prognon P; Borget I
    J Biomed Inform; 2016 Feb; 59():201-8. PubMed ID: 26705065
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
    Hughes-Wilson W; Palma A; Schuurman A; Simoens S
    Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
    Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
    Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis.
    Fischer KE; Rogowski WH; Leidl R; Stollenwerk B
    Health Policy; 2013 Oct; 112(3):187-96. PubMed ID: 23664301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.